2,627 results match your criteria multiple aml


Meta-analysis of gene signatures and key pathways indicates suppression of JNK pathway as a regulator of chemo-resistance in AML.

Sci Rep 2021 Jun 14;11(1):12485. Epub 2021 Jun 14.

Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Islamic Republic of Iran.

The pathways and robust deregulated gene signatures involved in AML chemo-resistance are not fully understood. Multiple subgroups of AMLs which are under treatment of various regimens seem to have similar regulatory gene(s) or pathway(s) related to their chemo-resistance phenotype. In this study using gene set enrichment approach, deregulated genes and pathways associated with relapse after chemotherapy were investigated in AML samples. Read More

View Article and Full-Text PDF

Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation.

Cancer Gene Ther 2021 Jun 11. Epub 2021 Jun 11.

Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.

Cabozantinib is a potent tyrosine kinase inhibitor with multiple targets including MET, VEGFR2, RET, KIT, and FLT3. Cabozantinib is widely used for the treatment of medullary thyroid cancer and renal cell carcinoma. We recently suggested cabozantinib as a potential therapeutic alternative for acute myeloid leukemia (AML) patients with FLT3-internal tandem duplication (FLT3-ITD). Read More

View Article and Full-Text PDF

Unusual source of recurrent Corynebacterium bacteraemia in an immunocompromised patient.

BMJ Case Rep 2021 Jun 11;14(6). Epub 2021 Jun 11.

Respiratory Medicine, Prince Philip Hospital, Llanelli, UK.

We describe a unique case of a patient with acute myeloid leukaemia (AML), with recurring infections during chemotherapy from chronic nasal carriage of non-diphtherial Corynebacterium, who was eventually diagnosed as she presented with neutropaenic sepsis. Identifying (often multiple) sources of infection in immunocompromised patients is crucial but deciding whether multiple organisms, which in health are considered as commensals, are actually pathogenic during vulnerable states-can be clinically difficult. Our case highlights the efforts to correctly identify the actual source of this rare organism and the recognition of its pathogenic potential when other illnesses present. Read More

View Article and Full-Text PDF

Catheter-related bloodstream infection associated with multiple insertions of the peripherally inserted central catheter in patients with hematological disorders.

Sci Rep 2021 Jun 9;11(1):12209. Epub 2021 Jun 9.

Department of Hematology, Tottori Prefectural Central Hospital, 730 ezu, Tottori City, Tottori, 680-0901, Japan.

Patients with hematological disorders are treated with multiple cycles of chemotherapy. As a result, they often require multiple insertions of the peripherally inserted central catheter (PICC) for prolonged periods of time. Although PICCs have been widely used worldwide in various patients, the safety and feasibility of the multiple insertions of the PICC in this population have not been fully verified. Read More

View Article and Full-Text PDF

Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis.

Mol Oncol 2021 Jun 8. Epub 2021 Jun 8.

Department of Medicine, Haematology section, Haukeland University Hospital, Helse Bergen HF, Bergen, Norway.

Incidence, molecular presentation and outcome of acute myeloid leukaemia (AML) is influenced by sex, but little attention has been directed at untangling sex-related molecular and phenotypic differences between female and male patients. While increased incidence and poor risk is generally associated with a male phenotype, the poor prognostic FLT3 internal tandem duplication (FLT3-ITD) mutation and co-mutations with NPM1 and DNMT3A is overrepresented in female AML. Here, we investigated the relationship between sex and FLT3-ITD mutation status by comparing clinical data, mutational profiles, gene expression and ex vivo drug sensitivity in four cohorts: BeatAML, LAML-TCGA and two independent HOVON/SAKK cohorts, comprising 1755 AML patients in total. Read More

View Article and Full-Text PDF

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML.

Blood Adv 2021 Jun;5(11):2539-2549

Department of Pathology, UT Southwestern Medical Center, Dallas, TX.

The clinicopathologic features of DNA methyltransferase 3A (DNMT3A)-mutated de novo acute myeloid leukemia (AML), and the significance of variant type, variant allele frequency (VAF), and multiple concomitant DNMT3A mutations, remain poorly defined. We examined 104 DNMT3A-mutated de novo AML patients from 2 major centers. Most (82%) had normal karyotype (NK); R882H variants were frequent(38%). Read More

View Article and Full-Text PDF

Review of Venetoclax in CLL, AML and Multiple Myeloma.

J Pers Med 2021 May 24;11(6). Epub 2021 May 24.

Department of Haematology, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.

Venetoclax is a highly selective and effective B-cell lymphoma-2 (BCL-2) inhibitor, which is able to reinstate the apoptotic potential of cancer cells. With its full repertoire yet to be explored, it has changed the therapeutic landscape in haematological malignancies, and most particularly chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML) and multiple myeloma (MM). In CLL, it has shown remarkable efficacy both as monotherapy and in combination therapy. Read More

View Article and Full-Text PDF

Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia.

Int J Mol Sci 2021 May 28;22(11). Epub 2021 May 28.

Division of Hematology-Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Hanyang University Seoul Hospital, Seoul 51139, Korea.

Acute myeloid leukemia (AML) is a heterogenous hematopoietic neoplasm with various genetic abnormalities in myeloid stem cells leading to differentiation arrest and accumulation of leukemic cells in bone marrow (BM). The multiple genetic alterations identified in leukemic cells at diagnosis are the mainstay of World Health Organization classification for AML and have important prognostic implications. Recently, understanding of heterogeneous and complicated molecular abnormalities of the disease could lead to the development of novel targeted therapeutic agents. Read More

View Article and Full-Text PDF

Delineation of Molecular Lesions in Acute Myeloid Leukemia Patients at Diagnosis: Integrated Next Generation Sequencing and Cytogenomic Studies.

Genes (Basel) 2021 May 30;12(6). Epub 2021 May 30.

Victor Babes National Institute of Pathology, 050096 Bucharest, Romania.

Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by a wide range of genetic defects. Cytogenetics, molecular and genomic technologies have proved to be helpful for deciphering the mutational landscape of AML and impacted clinical practice. Forty-eight new AML patients were investigated with an integrated approach, including classical and molecular cytogenetics, array-based comparative genomic hybridization and targeted next generation sequencing (NGS). Read More

View Article and Full-Text PDF

Adverse events of radioimmunotherapy for non-Hodgkin lymphoma: A systematic review and meta-analysis.

Leuk Res 2021 May 11;108:106615. Epub 2021 May 11.

University of South Florida: Morsani College of Medicine, Tampa, United States.

Non-Hodgkin's lymphoma continues to be a highly prevalent entity in the general population. Currently, there are multiple treatment schemes based on chemotherapeutic agents with a great success rate. However, there is a non-negligible percentage of patients who may relapse or be refractory. Read More

View Article and Full-Text PDF

The landscape of gene co-expression modules correlating with prognostic genetic abnormalities in AML.

J Transl Med 2021 May 29;19(1):228. Epub 2021 May 29.

Department of Hematology, China-Japan Friendship Hospital, Yinghua East Street, Beijing, China.

Background: The heterogenous cytogenetic and molecular variations were harbored by AML patients, some of which are related with AML pathogenesis and clinical outcomes. We aimed to uncover the intrinsic expression profiles correlating with prognostic genetic abnormalities by WGCNA.

Methods: We downloaded the clinical and expression dataset from BeatAML, TCGA and GEO database. Read More

View Article and Full-Text PDF

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.

Lancet Haematol 2021 Jun;8(6):e422-e432

Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. Electronic address:

Background Lenalidomide maintenance improves progression-free survival for patients with multiple myeloma, although its optimal duration is unknown. Clearance of minimal residual disease (MRD) in the bone marrow results in superior outcomes, although its attainment or sustainment does not alter clinical decision-making. Studies that have evaluated MRD serially are limited in length. Read More

View Article and Full-Text PDF

CD123-targeted therapy in acute myeloid leukemia.

Expert Rev Hematol 2021 Jun 14:1-16. Epub 2021 Jun 14.

Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA.

Introduction: Acute myeloid leukemia (AML) results from the neoplastic transformation of a hematopoietic stem cell. While therapeutic progress has stagnated for several decades, recent progress in the genomic classification of AML has paved the way for multiple new drug approvals. These long-awaited achievements represent a paradigm shift in the approach to a disease that has largely been managed with conventional chemotherapy since the 1970s. Read More

View Article and Full-Text PDF

Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia.

JCO Precis Oncol 2021 14;5. Epub 2021 Jan 14.

McDonnell Genome Institute, Washington University School of Medicine, St Louis, MO.

Purpose: Physicians treating hematologic malignancies increasingly order targeted sequencing panels to interrogate recurrently mutated genes. The precise impact of these panels on clinical decision making is not well understood.

Methods: Here, we report our institutional experience with a targeted 40-gene panel (MyeloSeq) that is used to generate a report for both genetic variants and variant allele frequencies for the treating physician (the limit of mutation detection is approximately one AML cell in 50). Read More

View Article and Full-Text PDF
January 2021

SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA.

Blood Cancer Discov 2021 May 2;2(3):266-287. Epub 2019 Dec 2.

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

We discovered that the survival and growth of many primary acute myeloid leukemia (AML) samples and cell lines, but not normal CD34+ cells, are dependent on SIRT5, a lysine deacylase implicated in regulating multiple metabolic pathways. Dependence on SIRT5 is genotype-agnostic and extends to RAS- and p53-mutated AML. Results were comparable between SIRT5 knockdown and SIRT5 inhibition using NRD167, a potent and selective SIRT5 inhibitor. Read More

View Article and Full-Text PDF

Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.

NAR Cancer 2021 Jun 17;3(2):zcab018. Epub 2021 May 17.

Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06511, USA.

Mutations in the isocitrate dehydrogenase-1 and -2 (IDH1/2) genes were first identified in glioma and acute myeloid leukemia (AML), and subsequently found in multiple other tumor types. These neomorphic mutations convert the normal product of enzyme, α-ketoglutarate (αKG), to the oncometabolite 2-hydroxyglutarate (2HG). Our group recently demonstrated that 2HG suppresses the high-fidelity homologous recombination (HR) DNA repair pathway, resulting in a state referred to as 'BRCAness', which confers exquisite sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. Read More

View Article and Full-Text PDF

Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia.

Front Oncol 2021 4;11:663406. Epub 2021 May 4.

Tumor Immunology, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.

Background: Immune-checkpoint (IC) inhibitors have revolutionized the treatment of multiple solid tumors and defined lymphomas, but they are largely ineffective in acute myeloid leukemia (AML). The reason why especially PD1/PD-L1 blocking agents are not efficacious is not well-understood but it may be due to the contribution of different IC ligand/receptor interactions that determine the function of T cells in AML.

Methods: To analyze the interactions of IC ligands and receptors in AML, we performed a comprehensive transcriptomic analysis of FACS-purified leukemia stem/progenitor cells and paired bone marrow (BM)-infiltrating CD4 and CD8 T cells from 30 patients with AML. Read More

View Article and Full-Text PDF

Extramedullary Involvement in Acute Myeloid Leukemia. A Single Center Ten Years' Experience.

Mediterr J Hematol Infect Dis 2021 1;13(1):e2021030. Epub 2021 May 1.

Dipartimento di Scienze Radiologiche Radioterapiche ed Ematologiche - Fondazione Policlinico Universitario A. Gemelli, IRCCS - Università Cattolica del Sacro Cuore.

The incidence, risk factors, and prognostic significance of extramedullary involvement (EMI) in adult patients with acute myeloid leukemia (AML) have not been established yet. This study analyzed clinical and biological characteristics, the impact on prognosis, and the cumulative incidence of EMI in a monocentric retrospective series. All adult patients diagnosed with AML observed in our institution between January 2010 and December 2017 were included in the analysis. Read More

View Article and Full-Text PDF

Chronic medical conditions and late effects after acute myeloid leukaemia in adolescents and young adults: a population-based study.

Int J Epidemiol 2021 May;50(2):663-674

Division of Hematology and Oncology, Center for Oncology Hematology Outcomes Research and Training (COHORT), University of California, Davis, Sacramento, CA, USA.

Background: Curative-intent treatment of acute myeloid leukaemia (AML) can lead to multiple chronic medical conditions ('late effects'). Little is known about the burden of late effects in adolescent and young adult (AYA, 15-39 years) survivors of AML. We aimed to estimate the cumulative incidence and investigate the main predictors of late effects among these patients. Read More

View Article and Full-Text PDF

Expression and prognosis analyses of CASP1 in acute myeloid leukemia.

Aging (Albany NY) 2021 05 17;13(10):14088-14108. Epub 2021 May 17.

The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518107, Guangdong, People's Republic of China.

Caspase1 (CASP1) is a gene that encodes multiple proteins related to cell death. Nevertheless, the function of CASP1 in the pathogenesis of AML is still unclear. In the present study, a detailed analysis of cancer versus normal samples was performed to explore the relationship between CASP1 and leukemia. Read More

View Article and Full-Text PDF

Quantitation of ivosidenib in human plasma via LC-MS/MS and its application in clinical trials.

Bioanalysis 2021 Jun 17;13(11):875-889. Epub 2021 May 17.

Agios Pharmaceuticals Inc., 88 Sidney Street, Cambridge, MA 02139, USA.

Ivosidenib is a potent and selective small molecule inhibitor of mutant isocitrate dehydrogenase 1. Accurate measurement of ivosidenib is the key to ivosidenib pharmacokinetics in clinical trials. Quantitation of ivosidenib was conducted by using a stable isotope labeled compound (ivosidenib-d) as the internal standard. Read More

View Article and Full-Text PDF

Healthcare resource utilization and economic burden of antifungal management in patients with hematologic malignancy in Japan: a retrospective database study.

Curr Med Res Opin 2021 May 22:1-14. Epub 2021 May 22.

IQVIA Solutions Japan K.K, Tokyo, Japan.

Objective: To examine treatment patterns of real-world antifungal management of patients at high risk of invasive fungal infections (IFI) and evaluate healthcare resource utilization and costs associated with antifungal management of IFIs in Japan.

Methods: This retrospective, observational study extracted data from a hospital-based claims database for patients in Japan who either (a) underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), or (b) were hospitalized with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) and received chemotherapy during the study period of January 2010 to January 2019.

Results: 863 patients were included in the allo-HSCT cohort and 4498 patients were included in the AML/MDS cohort. Read More

View Article and Full-Text PDF

Acute Myelogenous Leukemia with the t(7;7)(p15;p22) Translocation, a Novel Simple Variant of t(7;11)(p15;p15) Translocation: First Description.

Case Rep Hematol 2021 19;2021:5529669. Epub 2021 Apr 19.

IMS Group, Shinmatsudo Central General Hospital, Department of Hematology, Chiba, Japan.

The t(7;11)(p15;p15) translocation is a recurrent genetic abnormality associated with acute myelogenous leukemia (AML). The translocation results in a fusion between the nucleoporin 98 and homeobox genes. We describe a case of AML with t(7; 7)(p15;p22) translocation, which is a novel simple variant of the t(7;11)(p15;p15) translocation. Read More

View Article and Full-Text PDF

An Immune Checkpoint-Related Gene Signature for Predicting Survival of Pediatric Acute Myeloid Leukemia.

J Oncol 2021 19;2021:5550116. Epub 2021 Apr 19.

Department of Pediatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.

Objective: The aim of this research was to create a new genetic signature of immune checkpoint-associated genes as a prognostic method for pediatric acute myeloid leukemia (AML).

Methods: Transcriptome profiles and clinical follow-up details were obtained in Therapeutically Applicable Research to Generate Effective Treatments (TARGET), a database of pediatric tumors. Secondary data was collected from the Gene Expression Omnibus (GEO) to test the observations. Read More

View Article and Full-Text PDF

Varying Outcomes among Patients with Large Angiomyolipomas according to the Treatment Method.

Urol Int 2021 May 12:1-7. Epub 2021 May 12.

Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.

Purpose: This study aimed to evaluate the outcomes of large angiomyolipoma (AML) treatment by selective arterial embolization (SAE) versus nephron-sparing surgery (NSS) using a robotic surgical system.

Materials And Methods: Between January 2011 and June 2018, we retrospectively reviewed 25 patients who underwent robot-assisted partial nephrectomy (RAPN) or SAE for large AMLs. Ten patients underwent RAPN, and 15 underwent SAE. Read More

View Article and Full-Text PDF

Integrated OMICs unveil the bone-marrow microenvironment in human leukemia.

Cell Rep 2021 May;35(6):109119

Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Electronic address:

The bone-marrow (BM) niche is the spatial environment composed by a network of multiple stromal components regulating adult hematopoiesis. We use multi-omics and computational tools to analyze multiple BM environmental compartments and decipher their mutual interactions in the context of acute myeloid leukemia (AML) xenografts. Under homeostatic conditions, we find a considerable overlap between niche populations identified using current markers. Read More

View Article and Full-Text PDF

[Complete remission after standard induction therapy in a patient with acute myeloid leukemia associated with double-minute chromosomes].

Rinsho Ketsueki 2021 ;62(4):245-250

Department of Hematology/Oncology, Konan Kosei Hospital.

Acute myeloid leukemia (AML) associated with double-minute chromosomes (dmin) is a rare condition and has a poor prognosis. A 68-year-old man with leukocytosis and thrombocytopenia was admitted to our hospital. Bone marrow aspiration showed that 79. Read More

View Article and Full-Text PDF

Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.

Eur J Haematol 2021 May 9. Epub 2021 May 9.

Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Objectives: The aim of this study was to determine risk factors for development of acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) in patients with multiple myeloma (MM).

Methods: We identified all patients diagnosed with MM in Sweden from January 1st, 1958 to December 31, 2011. A total of 26 627 patients were diagnosed with MM with during the study period. Read More

View Article and Full-Text PDF

Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Transplant Cell Ther 2021 May 6;27(5):408.e1-408.e6. Epub 2021 Feb 6.

Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France.

Few therapeutic options are available for patients with acute myeloid or lymphoblastic leukemia (AML/ALL) relapsing after a second allogeneic stem cell transplantation (alloSCT2). In selected patients a third allogeneic stem cell transplantation (alloSCT3) has been used, but no detailed analysis is available so far. The European Society for Blood and Marrow Transplantation (EBMT) registry was screened for patients with acute leukemia (AL) receiving alloSCT3 from an identical or alternative donor to treat AL in either haematological relapse or disease persistence after alloSCT2 between 2001 and 2018. Read More

View Article and Full-Text PDF

Advanced eco-friendly UV spectrophotometric approach for resolving overlapped spectral signals of antihypertensive agents in their binary and tertiary pharmaceutical dosage form.

Spectrochim Acta A Mol Biomol Spectrosc 2021 Sep 19;258:119855. Epub 2021 Apr 19.

Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City 11829, Cairo, Egypt. Electronic address:

Cardiovascular disorders are among the foremost causes of death worldwide, especially hypertension, a silent killer syndrome that requires multiple drug therapy for proper management. This work presents novel and green spectrophotometric methods for the concurrent analysis of Amlodipine (AML), Telmisartan (TEL), Hydrochlorothiazide (HCTZ), and Chlorthalidone (CLO) in their pharmaceutical dosage form. The suggested methods were Fourier-self deconvolution, amplitude factor, and first derivative methods developed and validated for the simultaneous determination of a tertiary mixture of AML, TEL, and HCTZ in TELVAS 3D 80 mg tablet and a binary mixture of TEL and CLO in TELMIKIND-CT 40 tablets. Read More

View Article and Full-Text PDF
September 2021